← SynDRA
TOMIVOSERTIB
SynDRA canonical compound SYN0039251 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MKNK1 | MKNK2 |
|---|
| Mechanism of action | MAPK-interacting kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MKNK2 INHIBITOR
- MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor
- MKNK1 INHIBITOR
- CLK4 INHIBITOR
- STK17A INHIBITOR
- MAPK-interacting kinase inhibitor
Cross-references
Synonyms
- EFT-508
- eFT508
- CPD 23
- N45
- TOMIVOSERTIB (EFT-508)
- EFT508
- EFT 508
- UNII-U2H19X4WBV
- U2H19X4WBV
- Tomivosertib [INN]
- Tomivosertib [USAN]
- SCHEMBL17362622
- GTPL10167
- eFT-508 (eFT508)
- MolPort-044-560-418
- BCP18993
- EX-A2494
- ZINC575623807
- AKOS030627405
- CS-5841
- compound 23 [PMID: 29526098]
- HY-100022
- S8275
- 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione
- 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
- tomivosertibum
- RefChem:933186
- DTXCID801507219
- eFT508; Tomivosertib
- Tomivosertib (eFT-508)
- eFT508 HCl
- eFT508(Tomivosertib)?
- Tomivosertib (USAN/INN)
- Tomivosertib [USAN:INN]
- eFT-508 HCl
- TOMIVOSERTIB [WHO-DD]
- orb1304174
- SCHEMBL29359358
- GLXC-10728
Look up TOMIVOSERTIB in the interactive SynDRA portal →